135 related articles for article (PubMed ID: 25302366)
1. A20 expressing tumors and anticancer drug resistance.
da Silva CG; Minussi DC; Ferran C; Bredel M
Adv Exp Med Biol; 2014; 809():65-81. PubMed ID: 25302366
[TBL] [Abstract][Full Text] [Related]
2. A20--an omnipotent protein in the liver: prometheus myth resolved?
da Silva CG; Cervantes JR; Studer P; Ferran C
Adv Exp Med Biol; 2014; 809():117-39. PubMed ID: 25302369
[TBL] [Abstract][Full Text] [Related]
3. ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling.
Verstrepen L; Carpentier I; Verhelst K; Beyaert R
Biochem Pharmacol; 2009 Jul; 78(2):105-14. PubMed ID: 19464428
[TBL] [Abstract][Full Text] [Related]
4. Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20.
Sisto M; Barca A; Lofrumento DD; Lisi S
Clin Exp Immunol; 2016 May; 184(2):183-96. PubMed ID: 26724675
[TBL] [Abstract][Full Text] [Related]
5. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.
Düwel M; Welteke V; Oeckinghaus A; Baens M; Kloo B; Ferch U; Darnay BG; Ruland J; Marynen P; Krappmann D
J Immunol; 2009 Jun; 182(12):7718-28. PubMed ID: 19494296
[TBL] [Abstract][Full Text] [Related]
6. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN.
Heyninck K; De Valck D; Vanden Berghe W; Van Criekinge W; Contreras R; Fiers W; Haegeman G; Beyaert R
J Cell Biol; 1999 Jun; 145(7):1471-82. PubMed ID: 10385526
[TBL] [Abstract][Full Text] [Related]
7. Functional redundancy of the zinc fingers of A20 for inhibition of NF-kappaB activation and protein-protein interactions.
Klinkenberg M; Van Huffel S; Heyninck K; Beyaert R
FEBS Lett; 2001 Jun; 498(1):93-7. PubMed ID: 11389905
[TBL] [Abstract][Full Text] [Related]
8. Functional dichotomy of A20 in apoptotic and necrotic cell death.
Storz P; Döppler H; Ferran C; Grey ST; Toker A
Biochem J; 2005 Apr; 387(Pt 1):47-55. PubMed ID: 15527421
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Bredel M; Bredel C; Juric D; Duran GE; Yu RX; Harsh GR; Vogel H; Recht LD; Scheck AC; Sikic BI
J Clin Oncol; 2006 Jan; 24(2):274-87. PubMed ID: 16365179
[TBL] [Abstract][Full Text] [Related]
10. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
[TBL] [Abstract][Full Text] [Related]
11. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation.
Song HY; Rothe M; Goeddel DV
Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6721-5. PubMed ID: 8692885
[TBL] [Abstract][Full Text] [Related]
12. A20 inhibits human salivary adenoid cystic carcinoma cells invasion via blocking nuclear factor-kappaB activation.
Zhang B; Guan CC; Chen WT; Zhang P; Yan M; Shi JH; Qin CL; Yang Q
Chin Med J (Engl); 2007 Oct; 120(20):1830-5. PubMed ID: 18028781
[TBL] [Abstract][Full Text] [Related]
13. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.
Balkhi MY; Iwenofu OH; Bakkar N; Ladner KJ; Chandler DS; Houghton PJ; London CA; Kraybill W; Perrotti D; Croce CM; Keller C; Guttridge DC
Sci Signal; 2013 Jul; 6(286):ra63. PubMed ID: 23901138
[TBL] [Abstract][Full Text] [Related]
14. A20: linking a complex regulator of ubiquitylation to immunity and human disease.
Ma A; Malynn BA
Nat Rev Immunol; 2012 Nov; 12(11):774-85. PubMed ID: 23059429
[TBL] [Abstract][Full Text] [Related]
15. Cystic Fibrosis from Laboratory to Bedside: The Role of A20 in NF-κB-Mediated Inflammation.
Bannon A; Zhang SD; Schock BC; Ennis M
Med Princ Pract; 2015; 24(4):301-10. PubMed ID: 25925366
[TBL] [Abstract][Full Text] [Related]
16. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology.
Vereecke L; Beyaert R; van Loo G
Trends Immunol; 2009 Aug; 30(8):383-91. PubMed ID: 19643665
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection.
Liuwantara D; Elliot M; Smith MW; Yam AO; Walters SN; Marino E; McShea A; Grey ST
Diabetes; 2006 Sep; 55(9):2491-501. PubMed ID: 16936197
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Low Expression of A20 in Tumor Necrosis Factor-α-stimulated SLE Monocytes Mediates Sustained NF-κB Inflammatory Response.
Shi X; Qian T; Li M; Chen F; Chen Y; Hao F
Immunol Invest; 2015; 44(5):497-508. PubMed ID: 26107748
[TBL] [Abstract][Full Text] [Related]
19. Proinflammatory mediators alter expression of nuclear factor kappa B-regulating deubiquitinases in sinonasal epithelial cells.
Li P; Wang Y; Turner JH
Int Forum Allergy Rhinol; 2015 Jul; 5(7):583-9. PubMed ID: 25907801
[TBL] [Abstract][Full Text] [Related]
20. Combined expression of A1 and A20 achieves optimal protection of renal proximal tubular epithelial cells.
Kunter U; Daniel S; Arvelo MB; Choi J; Shukri T; Patel VI; Longo CR; Scali ST; Shrikhande G; Rocha E; Czismadia E; Mottley C; Grey ST; Floege J; Ferran C
Kidney Int; 2005 Oct; 68(4):1520-32. PubMed ID: 16164629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
